var data={"title":"Mometasone (nasal): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Mometasone (nasal): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/390074?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=mometasone-nasal-drug-information\" class=\"drug drug_general\">see &quot;Mometasone (nasal): Drug information&quot;</a> and <a href=\"topic.htm?path=mometasone-nasal-patient-drug-information\" class=\"drug drug_patient\">see &quot;Mometasone (nasal): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775137\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Nasonex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775138\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Mometasone;</li>\n      <li>Mosaspray;</li>\n      <li>Nasonex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10503094\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anti-inflammatory Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Corticosteroid, Intranasal</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Glucocorticoid</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10503126\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=mometasone-nasal-drug-information\" class=\"drug drug_general\">see &quot;Mometasone (nasal): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nasal airway obstruction/adenoidal hypertrophy:</b> Intranasal: Limited data available: Children and Adolescents 3-15 years: Initial 100 mcg once daily delivered as 50 mcg (1 spray) <b>per nostril</b> once daily for 6 weeks, followed by the same dose given every 24 hours for the first 2 weeks of each month.  Dosing based on two studies: The first was a randomized, placebo-controlled study (n=122; treatment arm: 67; age range; 3-15 years) in which patients received therapy for 6 weeks and 67.2% had a significant decrease in adenoid size compared to the control group (p&lt;0.001) (Cengel, 2005). The second was a 2-stage, placebo-controlled, randomized study (n=60, treatment arm: 30; age range: 3-7 years) which showed that after 40 days of daily mometasone therapy, ~77.7% of patients were considered responders and able to avoid adenoidectomy; those who responded continued therapy every 24 or 48 hours for the first 2 weeks of three subsequent months (Berlucchi, 2007). Long-term analysis of children receiving the daily dose for the first 2 weeks of each month continued to show improvement after a mean followup period of 28 months and the need for surgery remained reduced (Berlucchi, 2008). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Allergic rhinitis:</b> Intranasal:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment:  </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 2-11 years: 100 mcg once daily delivered as 50 mcg (1 spray) <b>per nostril</b> once daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents:  200 mcg once daily delivered as 100 mcg (2 sprays) <b>per nostril</b> once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prevention: Children &ge;12 years and Adolescents: 200 mcg once daily delivered as 100 mcg (2 sprays) <b>per nostril</b> once daily beginning 2-4 weeks prior to pollen season</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nasal polyps, treatment:</b> Intranasal: Adolescents &ge;18 years: 200 mcg twice daily delivered as 100 mcg (2 sprays) <b>per nostril</b> twice daily; a lower dose of  200 mcg once daily delivered as 100 mcg (2 sprays) <b>per nostril</b> once daily may be effective in some patients</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Allergic rhinitis:</b> Intranasal: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: 200 mcg once daily delivered as 100 mcg (2 sprays) <b>per nostril</b> once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prevention: 200 mcg once daily delivered as 100 mcg (2 sprays) <b>per nostril</b> once daily beginning 2-4 weeks prior to pollen season</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nasal polyps, treatment:</b> Intranasal: 200 mcg twice daily delivered as 100 mcg (2 sprays) <b>per nostril</b> twice daily; 200 mcg once daily delivered as 100 mcg (2 sprays) <b>per nostril</b> once daily may be effective in some patients</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling. Mometasone concentrations appear to increase with the severity of hepatic impairment; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775337\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Nasal, as furoate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nasonex: 50 mcg/actuation (17 g) [contains benzalkonium chloride, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mcg/actuation (17 g)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775140\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21005930\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=mometasone-nasal-drug-information\" class=\"drug drug_general\">see &quot;Mometasone (nasal): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Nasonex 17 g bottles contain 120 sprays.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10503127\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Shake well prior to each use.  Before first use, prime by pressing pump 10 times or until a fine spray appears. Repeat priming with 2 sprays or until a fine spray appears if &ge;1 week between use. Blow nose to clear nostrils before each use. Insert applicator into nostril, keeping bottle upright, and close off the other nostril. Breathe in through nose. While inhaling, press pump to release spray. Do not spray into eyes or mouth. Discard after labeled number of doses has been used, even if bottle is not completely empty.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">After removing nasal spray from container, avoid prolonged exposure of product to direct light; brief exposure to light (with normal use) is acceptable. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775225\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10503104\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Management of nasal symptoms associated with seasonal and perennial allergic rhinitis (FDA approved in ages &ge;2 years and adults); prevention of seasonal allergic rhinitis (FDA approved in ages &ge;12 years and adults); treatment of nasal polyps (FDA approved in adults); has also been used for management of nasal airway obstruction associated with adenoidal hypertrophy</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Intranasal corticosteroids have also been used as an adjunct to antibiotics in empiric treatment of acute bacterial rhinosinusitis primarily in patients with history of allergic rhinitis (Chow, 2012) and in pediatric patients with mild obstructive sleep apnea syndrome who cannot undergo adenotonsillectomy or who still have symptoms after surgery (Marcus, 2012). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775196\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, dyspepsia, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Dysmenorrhea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Viral infection (nasal inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Musculoskeletal pain, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Conjunctivitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Otitis media</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Asthma, cough (nasal inhalation), epistaxis, flu-like symptoms, nasal mucosa irritation, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Altered sense of smell (rare), anaphylaxis, angioedema, burning sensation of the nose, dysgeusia (rare), growth suppression, nasal candidiasis, nasal mucosa ulcer, nasal septum perforation, oral candidiasis (nasal inhalation)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775191\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to mometasone or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for corticosteroids is limited. However, the possibility of cross-sensitivity cannot be ruled out with certainty because of similarities in chemical structure and/or pharmacologic actions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775192\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: When recommended doses are exceeded, or in extremely sensitive individuals, may cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis. Reports consistent with hypercortisolism are rare. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do <b>not</b> provide the systemic steroid needed to treat patients having trauma, surgery, or infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Delayed wound healing: Avoid nasal corticosteroid use in patients with recent nasal septal ulcers, nasal surgery, or nasal trauma until healing has occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity reactions including wheezing have been reported; discontinue if such reactions occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Avoid exposure to chickenpox and/or measles, especially if not immunized.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Local nasal effects: Nasal septum perforation, epistaxis and localized <i>Candida albicans</i> infections of the nose and/or pharynx may occur. Periodically examine nasal mucosa in patients on long term therapy; discontinuation of therapy may be necessary if an infection occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment: drug accumulation may increase with severity of hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: Use caution or avoid in patients with active or latent tuberculosis or in patients with untreated fungal, bacterial, systemic viral infections, or ocular herpes simplex; worsening of these conditions may occur. Do not use in untreated localized infection involving the nasal mucosa; concurrent antimicrobial therapy should be administered if bacterial infection of the sinuses is suspected/confirmed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in chronic users or in patients who report visual changes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Avoid using higher than recommended dosages; suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, or hypercortisolism (Cushing syndrome) may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients, even at recommended doses via intranasal route (monitor growth).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Prior to use, the dose and duration of treatment should be based on the risk vs benefit for each individual patient. In general, use the smallest effective dose for the shortest duration of time to minimize adverse events. A gradual tapering of dose may be required prior to discontinuing therapy. There have been reports of systemic corticosteroid withdrawal symptoms (eg, joint/muscle pain, lassitude, depression) when withdrawing inhalation therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775199\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775200\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16021&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Corticosteroids (Nasal) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775186\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775187\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Intranasal corticosteroids, including mometasone, may be acceptable for the treatment of rhinitis during pregnancy when used at recommended doses (Lal 2016; Wallace 2008). Pregnant women adequately controlled on mometasone may continue therapy; if initiating treatment during pregnancy, use of an agent with more data in pregnant women may be preferred (Namazy 2016; Wallace 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10503128\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Mucous membranes for signs of fungal infection, growth (pediatric patients), signs/symptoms of HPA axis suppression/adrenal insufficiency; ocular changes </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775226\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins). Leukocytes and macrophages may have to be present for the initiation of responses mediated by the above substances. Inhibits the margination and subsequent cell migration to the area of injury, and also reverses the dilatation and increased vessel permeability in the area resulting in decreased access of cells to the sites of injury.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775228\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Improvement in allergic rhinitis symptoms may be seen within 11 hours; Maximum effect: Within 1 to 2 weeks after starting therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Undetectable in plasma; clinical effects are due to direct local effect, rather than systemic absorption</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 98% to 99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; extensive via CYP3A4 to multiple metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: &lt;1%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 6 hours (IV)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Bile (primary route): urine (limited)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21207441\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">When  used short term as adjunctive therapy in acute bacterial rhinosinusitis (ABRS), intranasal steroids show modest symptomatic improvement and few adverse effects; improvement is primarily due to increased sinus drainage. Use should be considered optional in ABRS; however, intranasal corticosteroids should be routinely prescribed to ABRS patients who have a history of or concurrent allergic rhinitis (Chow, 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775339\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Implant</b> (Propel Mini Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">370 mcg (1): $990.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Implant</b> (Sinuva Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1350 mcg (1): $1,530.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Mometasone Furoate Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg/ACT (17 g): $266.93</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Nasonex Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg/ACT (17 g): $301.72</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961990\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Avocom (KW, SA);</li>\n      <li>Cobizal (KR);</li>\n      <li>Defonex (KW, SA);</li>\n      <li>Metanase (BD);</li>\n      <li>Metaspray (IN, LK);</li>\n      <li>Mometomark (LK);</li>\n      <li>Monitazon (KR);</li>\n      <li>Mosaspray (PH);</li>\n      <li>Narinex (KR);</li>\n      <li>Nasaflex (KR);</li>\n      <li>Nasative (KR);</li>\n      <li>Nasocobi (KR);</li>\n      <li>Nasomet (BD, PT);</li>\n      <li>Nasonex (AE, AR, AT, AU, BE, BG, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IL, IS, IT, JO, JP, KW, LB, LK, LT, LV, MT, NI, NL, NO, PA, PE, PH, PL, QA, RO, RU, SA, SE, SI, SK, SV, TH, TR, TW, UY, VE, VN);</li>\n      <li>Nasonex Nasal Spray (AU, DE, EE, GB, HK, ID, IE, KR, MY, PH, SG);</li>\n      <li>Nazoneks (UA);</li>\n      <li>Nezelex (KR);</li>\n      <li>Rinobudex (EC, PE);</li>\n      <li>Sinocort (JO);</li>\n      <li>Tabunex (JO, QA);</li>\n      <li>Uniclar (CO);</li>\n      <li>Zalconex (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Berlucchi M, Salsi D, Valetti L, et al, &quot;The Role of Mometasone Furoate Aqueous Nasal Spray in the Treatment of Adenoidal Hypertrophy in the Pediatric Age Group: Preliminary Results of a Prospective, Randomized Study,&quot; <i>Pediatrics</i>, 2007, 119(6):e1392-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mometasone-nasal-pediatric-drug-information/abstract-text/17533178/pubmed\" target=\"_blank\" id=\"17533178\">17533178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berlucchi M, Valetti L, Parrinello G, et al, &quot;Long-Term Follow-Up of Children Undergoing Topical Intranasal Steroid Therapy For Adenoidal Hypertrophy,&quot;<i> Int J Pediatr Otorhinolaryngol</i>, 2008, 72(8):1171-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mometasone-nasal-pediatric-drug-information/abstract-text/18499270/pubmed\" target=\"_blank\" id=\"18499270\">18499270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cengel S and Akyol MU, &quot;The Role of Topical Nasal Steroids in the Treatment of Children With Otitis Media With Effusion and/or Adenoid Hypertrophy,&quot; <i>Int J Pediatr Otorhinolaryngol</i>, 2006, 70(4):639-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mometasone-nasal-pediatric-drug-information/abstract-text/16169093/pubmed\" target=\"_blank\" id=\"16169093\">16169093</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow AW, Benninger MS, Brook I, et al, &quot;IDSA Clinical Practice Guideline For Acute Bacterial Rhinosinusitis in Children and Adults,&quot; <i>Clin Infect Dis</i>, 2012, 54(8):e72-e112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mometasone-nasal-pediatric-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marcus CL, Brooks LJ, Draper KA, et al, &quot;Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome,&quot; <i>Pediatrics</i>, 2012, 130(3):576-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mometasone-nasal-pediatric-drug-information/abstract-text/22926173/pubmed\" target=\"_blank\" id=\"22926173\">22926173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    NAEPP Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at  <a href=\"http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wallace DV, Dykewicz MS, Bernstein DI, et al, &quot;The Diagnosis and Management of Rhinitis: An Updated Practice Parameter,&quot; <i>J Allergy Clin Immunol</i>, 2008, 122(2 Suppl):S1-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mometasone-nasal-pediatric-drug-information/abstract-text/18662584/pubmed\" target=\"_blank\" id=\"18662584\">18662584</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16021 Version 110.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8775137\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8775138\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10503094\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10503126\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8775337\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F8775140\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21005930\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10503127\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F8775225\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10503104\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8775196\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8775191\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8775192\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8775199\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8775200\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8775186\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8775187\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10503128\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8775226\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F8775228\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F21207441\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8775339\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961990\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/16021|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=mometasone-nasal-drug-information\" class=\"drug drug_general\">Mometasone (nasal): Drug information</a></li><li><a href=\"topic.htm?path=mometasone-nasal-patient-drug-information\" class=\"drug drug_patient\">Mometasone (nasal): Patient drug information \t</a></li></ul></div></div>","javascript":null}